What question did this study set out to answer?

To compare arachidonic acid metabolic pathways and activation responses in platelets from patients with Philadelphia chromosome-positive chronic myelogenous leukemia versus healthy controls.

October 1, 1980BloodOpen Access

Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia

View Full Paper

Ask AI

Bookmark

Why the study?

Is platelet arachidonic acid metabolism altered in patients with chronic myelogenous leukemia compared to normal subjects?

Population

10 patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and 7 normal subjects

Comparison

In vitro incubation of platelets with… vs Platelets from normal subjects

Design

Case-control

Authors

JSJubelirer SjWest Virginia Library Commission FRFeimata RusselMinistry of Health and Sanitation RVR. VaillancourtInstitut Universitaire de Cardiologie et de Pneumologie de Québec

Discussion

Member takes

Implication

Impaired thrombin-induced arachidonic acid release may heighten bleeding risk in CML; this case-control observation leaves open normalization after chemotherapy and requires confirmation.

Key Points

To compare arachidonic acid metabolic pathways and activation responses in platelets from patients with Philadelphia chromosome-positive chronic myelogenous leukemia versus healthy controls.
Analyzed platelets from 10 patients with Philadelphia chromosome-positive chronic myelogenous leukemia and 7 healthy control subjects.
Incubated isolated platelets with 3H-arachidonic acid, stimulated them with thrombin (5 U/ml), and quantified released cyclooxygenase and lipoxygenase products using high pressure liquid chromatography.
Thrombin-induced release of 3H-arachidonic acid metabolites was significantly reduced in chronic myelogenous leukemia platelets compared with control platelets (19.0% ± 7.4% vs 32.3% ± 4.9%, p < 0.01), with declines across both cyclooxygenase and lipoxygenase pathways.
Metabolite release was lowest in three patients with accelerated-phase disease, and severe metabolic defects fully normalized in one patient evaluated after successful hydroxyurea chemotherapy.

Structured PICO

Is platelet arachidonic acid metabolism altered in patients with chronic myelogenous leukemia compared to normal subjects?

Population

10 patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and 7 normal subjects

Intervention

In vitro incubation of platelets with 3H-arachidonic acid and treatment with thrombin (5 U/ml)

Comparator

Platelets from normal subjects

Outcome

Release of radioactivity (arachidonic acid metabolites) in response to thrombinsurrogate

Platelets from patients with CML show impaired arachidonic acid metabolism and reduced release of metabolites in response to thrombin, which may normalize after successful chemotherapy.

Cite This Study

Sj et al. (1980) studied this question.

synapsesocial.com/papers/6a730bafd78d4e840ea8f666 https://doi.org/10.1182/blood.v56.4.728.728

View Full Paper

Ask AI

Bookmark

Implication

Impaired thrombin-induced arachidonic acid release may heighten bleeding risk in CML; this case-control observation leaves open normalization after chemotherapy and requires confirmation.

Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider